MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 90
Updated:10/27/2018
Start Date:August 24, 2018
End Date:December 30, 2023
Contact:Sharanya Chandrasekhar, M.S.
Email:shc2043@med.cornell.edu
Phone:646-962-2196

Use our guide to learn which trials are right for you!

Prostate SBRT is a standard of care treatment for prostate cancer that has not spread to
distant metastatic sites. Radiation is delivered to the prostate and seminal vesicles in 5
treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated
good outcomes with acceptable toxicity. In this initial study, MRI guided treatment planning
and delivery will be used to deliver 7 Gy to the entire prostate and seminal vesicles, with a
selective boost of additional 0.5, 1.0, 1.5 or 2 Gy per fraction for total dose of 37.5, 40,
42.5 or 45 Gy to biopsy proven lesions, defined using MRI.

Prostate SBRT is a standard of care treatment for prostate cancer that has not spread to
distant metastatic sites. Radiation is delivered to the prostate and seminal vesicles in 5
treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated
good outcomes with acceptable toxicity. In this initial study, MRI guided treatment planning
and delivery will be used to deliver 7 Gy to the entire prostate and seminal vesicles, with a
selective boost of additional 0.5, 1.0, 1.5 or 2 Gy per fraction for total dose of 37.5, 40,
42.5 or 45 Gy to biopsy proven lesions, defined using MRI.

Hypothesis: MRI-guided treatment planning and delivery can selectively target high-risk
prostate nodules and deliver a higher radiation dose, to achieve maximal local control
without increasing treatment toxicity

Inclusion Criteria:

- Biopsy-proven diagnosis of prostate adenocarcinoma

- NCCN defined low-, intermediate- and high-risk prostate cancer

- Age ≥ 18

- Patient must have prostate MRI with a PIRADS 4 or 5 lesion

Exclusion Criteria:

- History of prior pelvic radiation (external beam or brachytherapy)

- History of TURP

- Inability to undergo MRI

- Patients with metastatic disease (other than pelvic lymph nodes) are ineligible for
this study

- AUA score >17
We found this trial at
1
site
New York, New York 10065
Principal Investigator: Josephine Kang, M.D.
Phone: 646-962-2196
?
mi
from
New York, NY
Click here to add this to my saved trials